SCYNEXIS Stock

SCYNEXIS Financial Leverage

The Financial Leverage (Equity Multiplier) of SCYNEXIS (SCYX) as of Aug 5, 2026 is 1.65. In the previous year, Financial Leverage (Equity Multiplier) was 1.76 — a change of -6.49% (lower).

Financial Leverage

1.65

YoY

-6.49%

Last updated:

Financial Leverage (Equity Multiplier) of SCYNEXIS is 2026 1.65 . Financial Leverage (Equity Multiplier) of SCYNEXIS was 2025 1.76 . It decreases by -6.49% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Financial Leverage (Equity Multiplier) of SCYNEXIS is 1.65 in 2026.

Financial Leverage (Equity Multiplier) of SCYNEXIS changed from 1.76 to 1.65, representing a -6.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — SCYNEXIS

All Key Metrics — SCYNEXIS